Syros Pharmaceuticals Inc SY-2101 in APL-Call Transcript
Good day, and thank you for standing by. Welcome to the Syros Pharmaceuticals Conference Call. (Operator Instructions) I would now like to hand the conference over to your speaker today, Nancy Simonian. Chief Executive Officer of Syros. Please go ahead.
Thank you. Good morning, and welcome to our KOL webinar on SY-2101 in APL. We will be making forward-looking statements. You can find a full description of our risk factors on our website.
Slide 3. Today is the third in a series of KOL events on our targeted heme portfolio. We are very pleased to have Dr. Farhad Ravandi, Professor of Medicine and Chief of Section of AML in the Department of Leukemia at the MD Anderson Cancer Center as our guest speaker today.
Slide 4, today's agenda. I will be making a few opening remarks Dr. Ravandi will discuss the treatment landscape and unmet need in APL. David Roth, our CMO, will give an overview of SY-2101 in APL, and we will
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |